These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 27207776

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
    Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, Rossi EA, Chang CH, Goldenberg DM.
    Bioconjug Chem; 2015 May 20; 26(5):919-31. PubMed ID: 25915780
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
    Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM.
    Oncotarget; 2015 Sep 08; 6(26):22496-512. PubMed ID: 26101915
    [Abstract] [Full Text] [Related]

  • 6. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
    Perrone E, Manara P, Lopez S, Bellone S, Bonazzoli E, Manzano A, Zammataro L, Bianchi A, Zeybek B, Buza N, Tymon-Rosario J, Altwerger G, Han C, Menderes G, Huang GS, Ratner E, Silasi DA, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD.
    Mol Oncol; 2020 Mar 08; 14(3):645-656. PubMed ID: 31891442
    [Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
    Han C, Perrone E, Zeybek B, Bellone S, Tymon-Rosario J, Altwerger G, Menderes G, Feinberg J, Haines K, Muller Karger ME, Bianchi A, Zammataro L, Manzano A, Bonazzoli E, Manara P, Buza N, Hui P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Lopez S, Santin AD.
    Gynecol Oncol; 2020 Feb 08; 156(2):430-438. PubMed ID: 31839338
    [Abstract] [Full Text] [Related]

  • 8. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
    Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura T, Nishio K, Nakagawa K, Tsurutani J.
    Int J Cancer; 2017 Oct 15; 141(8):1682-1689. PubMed ID: 28677116
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer.
    Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM.
    Clin Cancer Res; 2017 Jul 01; 23(13):3405-3415. PubMed ID: 28069724
    [Abstract] [Full Text] [Related]

  • 11. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
    Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ, Vahdat LT, Thomas SS, Govindan SV, Maliakal PP, Wegener WA, Hamburger SA, Sharkey RM, Goldenberg DM.
    Clin Cancer Res; 2015 Sep 01; 21(17):3870-8. PubMed ID: 25944802
    [Abstract] [Full Text] [Related]

  • 12. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
    Goldenberg DM, Sharkey RM.
    MAbs; 2019 Sep 01; 11(6):987-995. PubMed ID: 31208270
    [Abstract] [Full Text] [Related]

  • 13. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
    Yamazaki R, Nishiyama Y, Furuta T, Hatano H, Igarashi Y, Asakawa N, Kodaira H, Takahashi H, Aiyama R, Matsuzaki T, Yagi N, Sugimoto Y.
    Mol Cancer Ther; 2011 Jul 01; 10(7):1252-63. PubMed ID: 21566063
    [Abstract] [Full Text] [Related]

  • 14. The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer-Containing Antibody-Drug Conjugates.
    Corbett S, Huang S, Zammarchi F, Howard PW, van Berkel PH, Hartley JA.
    Mol Cancer Ther; 2020 Sep 01; 19(9):1856-1865. PubMed ID: 32669316
    [Abstract] [Full Text] [Related]

  • 15. Stable Isotope Dilution LC-HRMS Assay To Determine Free SN-38, Total SN-38, and SN-38G in a Tumor Xenograft Model after Intravenous Administration of Antibody-Drug Conjugate (Sacituzumab Govitecan).
    Pandey R, Gruslova A, Chiou J, Brenner AJ, Tiziani S.
    Anal Chem; 2020 Jan 07; 92(1):1260-1267. PubMed ID: 31765123
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.
    Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marmé F, Hong Q, Delaney RJ, Hafeez A, André F, Schmid P.
    Future Oncol; 2020 Apr 07; 16(12):705-715. PubMed ID: 32223649
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
    Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K.
    N Engl J Med; 2019 Feb 21; 380(8):741-751. PubMed ID: 30786188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.